Rodent brain tumor models have been very useful in advancing the treatment of glioblastomas. This review focuses on the four most widely used rodent brain tumor models: the C6, 9L, and F98 rat gliomas, and the GL261 murine glioma. All of these have been used in studies relating to boron neutron capture therapy. The most important of these studies were those using the 9L gliosarcoma, which led to the clinical use of boronophenylalanine, and the F98 glioma, which has been used for the preclinical evaluation of new boron delivery agents and methods of optimizing their delivery.
Get full access to this article
View all access options for this article.
References
1.
SahuU, BarthRF, OtaniY, et al.Rat and mouse brain tumor models for experimental neuro-oncology research. J Neuropathol Exp Neurol, 2022; 81(5):312–329; doi: 10.1093/jnen/nlac021.
2.
BendaP, LightbodyJ, SatoG, et al.Differentiated rat glial cell strain in tissue culture. Science, 1968; 161(3839):370–371; doi: 10.1126/science.161.3839.370.
3.
SchmidekHH, NielsenSL, SchillerAL, et al.Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg, 1971; 34 (3):335–340; doi: 10.3171/jns.1971.34.3.0335.
4.
NakagawaN, AkaiF, FukawaN, et al.Early effects of boron neutron capture therapy on rat glioma models. Brain Tumor Pathol, 2007; 24(1):7–13; doi: 10.1007/s10014-007-0214-4.
5.
BendaP, SomedaK, MesserJ, et al.Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg, 1971; 34(3):310–323; doi: 10.3171/jns.1971.34.3.0310.
6.
BarthRF, KaurB.Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol, 2009; 94(3):299–312; doi: 10.1007/s11060-009-9875-7.
7.
CoderreJA, GlassJD, FairchildRG, et al.Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res, 1990; 50(1):138–141.
8.
CoderreJA, JoelDD, MiccaPL, et al.Control of intracerebral gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat Res, 1992; 129(3):290–296; doi: 10.2307/3578028.
9.
MishimaY, HondaC, IchihashiM, et al.Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet, 1989; 2(8659):388–389; doi: 10.1016/s0140-6736(89)90567-9.
10.
CoderreJ, RubinP, FreedmanA, et al.Selective ablation of rat brain tumors by boron neutron capture therapy. Int J Radiat Oncol Biol Phys, 1994; 28(5):1067–1077; doi: 10.1016/0360-3016(94)90480-4.
11.
DiazAZ.Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol, 2003; 62(1–2):101–109; doi: 10.1007/BF02699937.
12.
SmilowitzHM, MiccaPL, NawrockyMM, et al.The combination of boron neutron-capture therapy and immunoprophylaxis for advanced intracerebral gliosarcomas in rats. J Neurooncol, 2000; 46(3):231–240; doi: 10.1023/a:1006409721365.
13.
NambaH, TagawaM, MiyagawaT, et al.Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir. Cancer Gene Ther, 2000; 7(6):947–953; doi: 10.1038/sj.cgt.7700172.
14.
MoriuchiS, WolfeD, TamuraM, et al.Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther, 2002; 9(9):584–591; doi: 10.1038/sj.gt.3301693.
15.
KoL, KoestnerA, WechslerW.Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol, 1980; 51(1):23–31; doi: 10.1007/BF00688846.
16.
BarthRF, YangW, RotaruJH, et al.Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res, 1997; 57(6):1129–1136.
17.
YangW, WuG, BarthRF, et al.Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res, 2008; 14(3):883–891; doi: 10.1158/1078-0432.CCR-07-1968.
18.
ElleaumeH, BarthRF, RousseauJ, et al.Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma. J Neurooncol, 2020; 149(2):193–208; doi: 10.1007/s11060-020-03600-x.
19.
TzengJJ, BarthRF, ClendenonNR, et al.Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res, 1990; 50(14):4338–4343.
20.
TzengJJ, BarthRF, OroszCG, et al.Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res, 1991; 51(9):2373–2378.
21.
VolovitzI, MarmorY, AzulayM, et al.Split immunity: Immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells. J Immunol, 2011; 187(10):5452–5462; doi: 10.4049/jimmunol.1003946
22.
AusmanJI, ShapiroWR, RallDP.Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res, 1970; 30(9):2394–2400.
23.
SzatmariT, LumniczkyK, DesaknaiS, et al.Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci, 2006; 97(6):546–553; doi: 10.1111/j.1349-7006.2006.00208.x.
24.
ChenJ, DaiQ, YangQ, et al.Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma. J Nanobiotechnology, 2022; 20(1):102; doi: 10.1186/s12951-022-01304-0.
25.
BarthRF, MiP, YangW.Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond), 2018; 38(1):35; doi: 10.1186/s40880-018-0299-7.
